A study group included 74 women with metabolically healthy obesity (MHO), estrogen-deficiency, and hypertension in the late fertile period (LFP); their mean age was 39.60±3.51 years) who was prescribed the antihypertensive agent Equamer as part of combination therapy. A control group consisted of 75 women with MHO in the LFP (their mean age was 39.50±3.49 years) with the normal level of estradiol and without hypertension. The study group was found to have an association of hypoestrogenism with psychoautonomic disorders, hypersymptopaticotonia, and cardialgia. After 6 months of therapy, the agent Equamer was shown to have a positive effect on the psychoautonomic status, the episodes of cardalgia in patients with estrogen-deficiency, MHO and hypertension in the LFP. Equamer has a high efficiency, is well tolerated by the patients (no adverse events were seen in the study), levels off the clinical manifestations of hypertension, normalizes blood pressure, lowers the body mass index, and exerts a complex harmonizing effect on a female organism.